Therapeutic co-administration of TGF-β-blocking and anti-PD-L1 antibodies reduced TGF-β in stromal cells, facilitated T-cell penetration, and induced vigorous anti-tumor immunity (Mariathasan et al., 2018). This evidence concerns the gene CD274 and neoplasm.